《復牌表現》金斯瑞(01548.HK)初段曾挫27%創逾年半低 涉違反內地進出口規定受查
金斯瑞生物科技(01548.HK)辦公地點涉違反中國進出口規定被查,該股今早(22日)復牌大幅低開22.2%,報10.8元後,初段曾跌27.1%,低見10.12元創2019年1月初後逾一年半低;屆今早9時52分報10.64元,跌幅逾23%,成交2,984萬股,涉3.15億元。
公司指上周五(18日)起短暫停牌,昨晚(21日)公布,上周四(17日),內地海關緝私部門對集團位於南京和鎮江的公司辦公地點進行了檢查。據了解,檢查是關於涉嫌違反中國法律關於進出口的規定。
在調查中,公司董事長、非執行董事兼控股股東之一章方良目前正處於在「監視居住」狀態。至今,集團4名其他員工被拘留訊問。相關監管機構尚未提供任何文件表明對章氏的監視居住與他擔任公司或任何子公司的高級管理人員或董事有關。公司補充,集團的業務營運維持正常。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.